Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients

Transplantation

Volumn 88, Issue 1, 2009, Pages 115-122

  Lehmkuhl, Hans B ^a   Arizon, José ^b   Viganò, Mario ^c   Almenar, Luis ^d   Gerosa, Gino ^e   Maccherini, Massimo ^f   Varnous, Shaida ^g   Musumeci, Francesco ^h   Hexham, J Mark ⁱ   Mange, Kevin C ⁱ   Livi, Ugolino ^j  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^c UNIVERSITY OF PAVIA   (Italy)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^f UNIVERSITY HOSPITAL OF SIENA   (Italy)

^g PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

more..

Author keywords

Cardiac transplantation; Cyclosporine; Everolimus; MMF; mTOR; PSI; Renal function

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; CREATININE; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN;

ACUTE GRAFT REJECTION; ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; BACTERIAL INFECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FEVER; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; INCIDENCE; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS; NAUSEA; OPEN STUDY; PERICARDIAL EFFUSION; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INFECTION; BIOPSY; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; EUROPE; GRAFT REJECTION; KIDNEY; KIDNEY DISEASE; KIDNEY FUNCTION TEST; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ADULT; BIOPSY; CREATININE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; EUROPE; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 67651008877     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181aacd22     Document Type: Article

References (12)

1. Keogh A. Calcineurin inhibitors in heart transplantation. J Heart Lung Transplant 2004; 23(5 Suppl): S202.
2. Crespo-Leiro MG. Calcineurin inhibitors in heart transplantation. Transplant Proc 2005; 37: 4018.
3. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847.
4. Wang S-S, Zuckermann A, Keogh AM, et al. Cyclosporine reduction in the presence of concentration-controlled everolimus in de novo cardiac transplantation: 6-month study results [abstract O326]. Presented at the 13th Congress of the European Society for Organ Transplantation, Prague, Czech. Republic, September 28-October 3, 2007.
5. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
6. Tedesco H, Pascual J, Magee J, et al. 36 months analysis on efficacy and safety of 2 doses of everolimus combined with reduced dose Neoral® in de novo kidney transplant recipients. Transplantation 2006; 82(Suppl 3): 499.
7. Whelchel J, Vitko S, Leone J, et al. 36 month result showing excellent graft function in de novo kidney transplant recipients treated with Certican®, Simulect® and reduced Neoral® exposure. Transplantation 2006; 82(Suppl 3): 302.
8. Pascual J. Concentration-controlled everolimus (Certican): Combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79 (9 Suppl): S76.
9. Lehmkuhl HB, Mai D, Dandel M, et al. Observational study with everolimus (Certican) in combination with low-dose cyclosporine in de novo heart transplant recipients. J Heart Lung Transplant 2007; 26: 700.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31.
11. Billingham ME, Cary NRB, Hammond EH, et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. J Heart Transplant 1990; 9: 587.
12. Eisen H, Kobashigawa J, Starling RC, et al. Improving outcomes in heart transplantation: The potential of proliferation signal inhibitors. Transplant Proc 2005; 37(suppl 4S): 4S.